Viramal Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Series B
  • (Cancelled)
  • Investors
  • 1

Viramal General Information

Description

Developer of transformative biological range of therapies designed to improve the quality of women's health worldwide. The company's therapies provide treatments for fertility, menopausal hormone therapy, contraception, vaginal dryness, and other sexual conditions with better safety, efficacy, and patient acceptability with fewer side effects, enabling women to take care of sensitive female reproductive areas with safety.

Contact Information

Website
www.viramal.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 106 New Bond Street
  • London W1S 1DN
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Viramal Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) Cancelled Generating Revenue
3. Later Stage VC (Series A) 03-Sep-2019 00.000 00.000 000.00 Completed Generating Revenue
2. Early Stage VC 01-Apr-2016 $4.81M $5.93M 000.00 Completed Generating Revenue
1. Angel (individual) 19-May-2014 $1.12M $1.12M 00.000 Completed Generating Revenue
To view Viramal’s complete valuation and funding history, request access »

Viramal Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.00
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 201,560 $0.012155 $1.52 $1.52 1x $1.52 7.04%
Ordinary 126,686 $0.012155 $1.06 $1.06 1x $1.06 4.43%
To view Viramal’s complete cap table history, request access »

Viramal Executive Team (6)

Name Title Board Seat Contact Info
Oliver Bates Co-Founder, Chief Executive Officer & Board Member
Peter Fitzwilliam Chief Financial Officer
Simon Holden Board Member & General Council and Company Secretary
Simona Fiore Ph.D Chief Medical Officer
Finn Larsen MD Chairman Of Science And Portfolio Development, Chief Medical and Development Officer, Board Member & Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Viramal Board Members (8)

Name Representing Role Since
Claus Frøkjær-Lorendsen Self Investment Board Observer 000 0000
GP Singh Self Board Member 000 0000
Jonathan Synett NCL Technology Ventures Board Member 000 0000
Nick Thornilley Self Board Member 000 0000
Oliver Bates Viramal Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Viramal Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viramal Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
NCL Technology Ventures Venture Capital Minority 000 0000 000000 0
To view Viramal’s complete investors history, request access »

Viramal Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 01-Mar-2015 000000000 00000 00 Buildings and Property 000000 00000
To view Viramal’s complete investments history, request access »